Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in ...

Oct 5 (Reuters) - AstraZeneca said on Monday it would spend more than $1 billion in Massachusetts as part of its broader $50 ...

The investment is expected to increase the pharma giant's workforce in Massachusetts to 3,000 employees within a few years.

CNBC’s Annika Kim Constantino and Pascal Soriot, AstraZeneca CEO, join 'The Exchange' to discuss its $50 billion investment in stateside manufacturing and opening an research and development site in ...

The 570,000-square-foot facility will house nearly 2,000 researchers and expand AstraZeneca's Massachusetts workforce by over 50% ...

Summit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, ...

Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its ...

AstraZeneca is advancing plans to expand clinical research in the Philippines, including a Manila center for clinical trials and proposed facilities focused on cancer and cardio-renal-metabolic ...

AstraZeneca has completed a $2 billion strategic equity investment in Summit Therapeutics, providing additional capital to accelerate development of ivonescimab across multiple solid tumor indications ...

CNBC’s Annika Kim Constantino and Pascal Soriot, AstraZeneca CEO, join 'The Exchange' to discuss its $50 billion investment ...

Massachusetts investment will expand the company’s state workforce by more than 50% and support research into next-generation ...

Summit Therapeutics Inc. ( SMMT) on Monday announced the closing of AstraZeneca's ( AZN) $2 billion strategic equity investment, which will support accelerated development of ivonescimab, an ...